176 related articles for article (PubMed ID: 27345628)
21. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer.
Yang YF; Xue SY; Lu ZZ; Xiao FJ; Yin Y; Zhang QW; Wu CT; Wang H; Wang LS
Gene Ther; 2014 Aug; 21(8):723-31. PubMed ID: 24849040
[TBL] [Abstract][Full Text] [Related]
23. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
24. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death.
Abou El Hassan MA; van der Meulen-Muileman I; Abbas S; Kruyt FA
J Virol; 2004 Nov; 78(22):12243-51. PubMed ID: 15507611
[TBL] [Abstract][Full Text] [Related]
25. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.
Oh JY; Park MY; Kim DR; Lee JH; Shim SH; Chung JH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
Int J Mol Med; 2010 Mar; 25(3):369-76. PubMed ID: 20127041
[TBL] [Abstract][Full Text] [Related]
26. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells.
Savontaus MJ; Sauter BV; Huang TG; Woo SL
Gene Ther; 2002 Jul; 9(14):972-9. PubMed ID: 12085246
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.
Hsiao WC; Sung SY; Liao CH; Wu HC; Hsieh CL
Mol Pharm; 2012 May; 9(5):1396-408. PubMed ID: 22480282
[TBL] [Abstract][Full Text] [Related]
29. Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.
Johnson TJ; Höti N; Liu C; Chowdhury WH; Li Y; Zhang Y; Lupold SE; Deweese T; Rodriguez R
Cancer Gene Ther; 2013 Jul; 20(7):394-402. PubMed ID: 23764901
[TBL] [Abstract][Full Text] [Related]
30. Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).
Azab BM; Dash R; Das SK; Bhutia SK; Sarkar S; Shen XN; Quinn BA; Dent P; Dmitriev IP; Wang XY; Curiel DT; Pellecchia M; Reed JC; Sarkar D; Fisher PB
J Cell Physiol; 2014 Jan; 229(1):34-43. PubMed ID: 23868767
[TBL] [Abstract][Full Text] [Related]
31. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
32. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
Sarkar D; Lebedeva IV; Su ZZ; Park ES; Chatman L; Vozhilla N; Dent P; Curiel DT; Fisher PB
Cancer Res; 2007 Jun; 67(11):5434-42. PubMed ID: 17545625
[TBL] [Abstract][Full Text] [Related]
33. Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.
Chai D; Qiu D; Zhang Z; Yuchen Shi S; Wang G; Fang L; Li H; Li H; Tian H; Zheng J
J Cell Mol Med; 2020 Sep; 24(18):10744-10755. PubMed ID: 32725966
[TBL] [Abstract][Full Text] [Related]
34. Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines.
Jiang YQ; Zhang Z; Cai HR; Zhou H
Int J Clin Exp Pathol; 2015; 8(11):13785-94. PubMed ID: 26823692
[TBL] [Abstract][Full Text] [Related]
35. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
[TBL] [Abstract][Full Text] [Related]
36. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
37. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
39. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
40. Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma.
Zhang M; Wang J; Li C; Hu N; Wang K; Ji H; He D; Quan C; Li X; Jin N; Li Y
Int J Oncol; 2013 Mar; 42(3):1052-60. PubMed ID: 23338489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]